Article: BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent.

Article: BioMarin in $289M deal for La Jolla lupus ...
Pharma Marketletter;  January 19, 2009 ;     505 words ... ... region. In the USA, BioMarin and La Jolla will jointly commercialize ... other territories, BioMarin will be fully responsible ... commercialization activities. BioMarin will receive a co ... commercialize Riquent and La Jolla could get up to $289 ...

Article: BioMarin Pharmaceutical Inc. (Novato CA) agreed to pay as ...
MondayMorning;  January 12, 2009 ;     660 words ...BIOMARIN PHARMACEUTICAL INC. (Novato ... much as $289 million to La Jolla Pharmaceutical Co. (San ... autoimmune disease lupus. BioMarin will pay $15 million in cash and equity up front to La Jolla, the companies said last ...

Article: BioMarin Top-Line Diminishing - Analyst Blog
Zacks Investment Research - Analyst Blog;  May 4, 2009 ;     700+ words ... ... Riquent In early Jan, 2009, BioMarin and La Jolla Pharmaceutical Company entered ... announcement, on Feb. 12, 2009 BioMarin announced that in the first ... failed to achieve its goal. BioMarin and La Jolla have decided to stop the study ...

Article: BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice ...
PR Newswire;  March 2, 2009 ;     700+ words ... ... PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced ... Fuchs will replace longtime BioMarin CMO, Dr. Emil Kakkis ... analysis of the ASPEN trial by La Jolla Pharmaceuticals; and those factors detailed in BioMarin's filings with the Securities ...

Article: BioMarin Rolls the Dice on $289M Deal for LJPC's Riquent ...
BIOWORLD Today;  January 8, 2009 ;     700+ words ... ... Trista Morrison, Staff Writer BioMarin Pharmaceutical Inc. agreed ... ex-Asia Pacific rights to La Jolla Pharmaceutical Co.'s Riquent ... wrote in a research note that BioMarin "structured this deal very ... Novato, Calif.-based BioMarin is paying San Diego-based ...

Article: BioMarin Downgraded to Hold - Analyst Blog
Zacks Investment Research - Analyst Blog;  February 20, 2009 ;     700+ words ... ... until the company can launch new products. BioMarin recently entered into an agreement with La Jolla Pharmaceutical Companyto develop and commercialize ... the continuation of the trial is futile. BioMarin and partnerLa Jolla Pharmaceuticalhave decided ...

Article: BioMarin Provides Update on Phenylase Product Development.
PR Newswire;  September 11, 2006 ;     700+ words ... ... of phenylketonuria (PKU). BioMarin plans to conduct additional ... Chief Medical Officer of BioMarin. "The data suggest that we ... Research Institute, located in La Jolla, California. About Phenylase ... phenylalanine hydroxylase. BioMarin is seeking to develop Phenylase ...